



ISHBT - Advocacy Team

Friday, 22th July, 2026

Delhi

The Indian Society of Haematology and Blood Transfusion (ISHBT) continues its dedicated advocacy efforts to strengthen and expand access to specialised haematology services across India. As part of this initiative, the ISHBT Advocacy Team held important discussions with Dr. Ranjan Choudhury, NHSRC, regarding key issues related to haematology healthcare delivery and policy. The team also met with Dr. Bijoy Deka, Deputy Commissioner, Medical (SST), Delhi, and discussed the inclusion of Haematology as a Super-speciality under the ESI Scheme for the management and treatment of haematological diseases, covering both benign and malignant disorders. Further, the ISHBT Advocacy Team engaged with the Office of the Drugs Controller General of India (DCGI) and its office bearers to discuss matters of importance to the haematology community and patients. These continued engagements reflect ISHBT's commitment to advocating for better recognition of the speciality, improved healthcare policies, wider access to specialised treatment,

and stronger patient care pathways for individuals with haematological disorders. ISHBT remains committed to working with policymakers, regulatory authorities and healthcare institutions towards strengthening haematology services in India

National Coagulation Conclave 2026

Friday & Saturday, 24th & 25th July, 2026

SGPGIMS, Lucknow

Lucknow, July 2026: The National Coagulation Conclave 2026, a two-day academic conference dedicated to advancing knowledge and clinical practice in coagulation and haemostasis, was held on 24th and 25th July 2026 at the Lecture Theatre Complex, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow.

Organised by the Department of Hematology, SGPGIMS, Lucknow, under the aegis of the Indian Society of Hematology and Blood Transfusion (ISHBT) and the Indian College of Hematology (ICH), the conclave will focus on the theme "Integrated Hemostasis: From Laboratory Insights to Clinical Practice."

The scientific programme will bring together eminent haematologists and experts from across the country to discuss recent advances and practical challenges in coagulation disorders. Key sessions will cover platelet disorders, haemophilia, inhibitors, non-factor therapies, gene therapy, von Willebrand disease, bleeding disorders in women, thrombophilia, lupus anticoagulant, TTP/HUS, acquired haemophilia,

paediatric and neonatal haemostasis, and laboratory coagulation. A special "Meet the Experts and Mentors" session will provide participants with an opportunity to discuss real-world clinical challenges and seek practical guidance from leading experts. The conclave will also feature oral presentations, a quiz, interactive panel discussions and case-based sessions.

The event is expected to provide an important platform for knowledge exchange, professional collaboration and strengthening integrated approaches to the diagnosis and management of bleeding and thrombotic disorders.



RAKTAVIGYAN 2026

RAKTAVIGYAN

Saturday & Sunday, 22nd & 23rd August, 2026

Patna, Bihar

Patna, Bihar: The 8th Annual Conference of the Hematology Foundation of Bihar – RAKTAVIGYAN 2026 will be held on Saturday and Sunday, 22nd & 23rd August 2026, at Hotel Chanakya, Patna, Bihar. Organised by the Hematology Foundation of Bihar, in association with the Indian Society of Hematology & Blood Transfusion (ISHBT) and the Indian College of Hematology (ICH), the conference will bring together leading haematologists, clinicians, researchers and healthcare professionals from across the country. The theme of RAKTAVIGYAN 2026, "Bridging the Care Gap – Advancing Hematology to Rural & Urban India," highlights the need to make quality haematology services accessible to patients across all sections of society. The conference will feature scientific discussions and knowledge-sharing on contemporary advances in haematology, with special emphasis on thalassemia screening, prevention and comprehensive patient care. The programme will also promote public awareness regarding pre-marital thalassemia screening, carrier detection and the importance of informing doctors about thalassemia status before pregnancy.

With the message "एक कदम जागरूकता की ओर, एक कदम स्वस्थ भविष्य की ओर", RAKTAVIGYAN 2026 aims to strengthen awareness, collaboration and equitable haematology care while encouraging the spirit of voluntary blood donation.

ISHBT Election 2026 - E-Voting Announcement

E-Voting Link will be activated from 1st September, 2026 at 10:00 A.M. to 15th September, 2026 till 05:00 P.M.



HAEMATOCON 2026
12th - 15th NOV, 2026 | Ahmedabad, India



Indian Society of Hematology & Blood Transfusion

67th Annual Conference of
Indian Society of Hematology & Blood Transfusion



HAEMATOCON 2026

Theme: - Advancing Hematology: From Evidence to Clinical Excellence

12th - 15th NOV, 2026 | Ahmedabad, India

Register Now - www.haematocon2026.in



SAVE THE DATE



29th - 30th
August 2026



Mayfair Waves
Puri, Odisha

Programme Director:
Prof. (Dr.) Rabindra Kumar Jena & Prof. (Dr.) Tuphan Kanti Dolai

Upcoming CMEs of ISHBT

HEMATO Conclave 2026

Organised by:
Indian Society of Haematology
and Blood Transfusion

Date: 29th - 30th August, 2026

Venue: Mayfair Waves, Puri, Odisha

Programme Director:
Prof. (Dr.) Rabindra Kumar Jena
& Prof. (Dr.) Tuphan Kanti Dolai



Indian Society of Haematology
and Blood Transfusion

49TH MASTER CLASS

TOPIC
Emergency Room
management of
Sickle Cell Disease

TIME
07:00 P.M. IST

DATE
19th Aug, 2026
Wednesday

Welcome Address: Dr. Rajni De
Chairperson: Dr. Rabindra Kumar Jena
Masterclass Talk
Question and Answer



Dr. Ashutosh Panigrahi
M.B.B.S., M.D.,
D.M. - Clinical Hematology

Additional Professor, Clinical Hematology Division,
Department of Medical Sciences / Hematology,
AIIMS, Bhubaneswar
Specialist in the Bone Marrow Transplant (BMT),
He has 20 years of experience in Hematology and has worked
as an expert in different cities in India.
The specialty interests in anaemia, bleeding and clotting
disorders, acute and chronic leukaemia, lymphoma and
syndromes.

Masterclass of ISHBT

49th Masterclass of ISHBT

Topic: Emergency Room management of
Sickle Cell Disease

Speaker: Dr. Ashutosh Panigrahi

Date: Wednesday, 19th August, 2026

Time: 07:00 P.M. IST

<https://forms.gle/9NawGZMZVginWKRo6>

Indian Journal of Haematology & Blood Transfusion (IJHBT)

Publishing model - Hybrid

Volume: 42, Issue: 4, July, 26

75 articles in this issue



Indian Journal of Hematology & Blood Transfusion

The Official Journal of The Indian Society of Hematology & Blood Transfusion

Best Practices for Thalassemia Management: Recommendations by Indian Society of Hematology and Blood Transfusion
Friederichsen - Total Body Irradiation-Based Myeloablative Conditioning for High-Dose Hematopoietic Stem Cell Transplantation & 10-Year Single-Center Real-World Analysis
Is Iron Overload Related to Cardiovascular Defects of Transfusion-Dependent Thalassemia Patients? Study of Digital Morphometry From Eastern India

Springer

Click below link to read or download

<https://link.springer.com/journal/12288/volumes-and-issues/42-4>

ISHBT Annual Circular 2026

Link to Download -
<https://ishbtish.com/imgs/circular/Annual%20Circular%202026.pdf>




ISHBT Election 2026 Circular

Link to Download -
<https://ishbtish.com/imgs/pdf/Election%20Circular%202026.pdf>

ISHBT Election 2026 - Nomination Form

Link to Download -
<https://ishbtish.com/imgs/pdf/Election%20Nomination%20Form%202026.pdf>

Guideline By Indian College of Hematology (ICH)



Available On

Jaypee Brothers Medical Publishers,
Amazon & AIBH

<https://ishbtish.com/ich/guidelines.html>

What's new in Haematology in Aug, 2026

Multiple myeloma: First approval of a new CELMoD agent

The US FDA approved iberdomide in combination with daratumumab and dexamethasone for relapsed or refractory multiple myeloma. Iberdomide is the first approved cereblon E3 ligase modulator (CELMoD) for this disease, expanding treatment options for patients whose myeloma has returned or become resistant to previous therapies.

Polycythaemia vera: A new approach to disease control

Rusfertide (Mimrylo) received US FDA approval in August for adults with polycythaemia vera. This hepcidin-mimetic therapy regulates iron availability and aims to control excessive red-cell production, reducing the need for therapeutic phlebotomy. Monitoring for anaemia and iron deficiency remains important.

Warm autoimmune haemolytic anaemia: First specifically approved treatment

Nipocalimab (Imaavy) received US FDA approval for warm autoimmune haemolytic anaemia in adults and children aged 12 years and older who have received corticosteroids previously or are currently receiving them. By blocking the neonatal Fc receptor (FcRn), the drug reduces circulating IgG autoantibodies that contribute to red-cell destruction. Approval was supported by the Phase 2/3 ENERGY study.

Essential thrombocythaemia: A new interferon-based option

The US FDA approved ropeginterferon alfa-2b-njft (Besremi) for adults with essential thrombocythaemia. The decision was supported by Phase 3 SURPASS-ET data showing improved durable responses compared with anagrelide. It represents a significant addition to treatment options for this chronic myeloproliferative neoplasm.

Teclistamab moves towards earlier-line multiple myeloma treatment

Phase 3 MajesTEC-9 findings showed substantial improvements in progression-free survival and response rates with teclistamab compared with standard regimens in relapsed or refractory myeloma after one to three prior treatment lines. However, severe and fatal infections were more frequent, highlighting the importance of infection prevention and immunoglobulin monitoring.

Mantle cell lymphoma: Promising bispecific antibody combination

A Phase 2 study of mosunetuzumab plus polatuzumab vedotin reported an overall response rate of 88.1% in heavily pretreated patients with relapsed or refractory mantle cell lymphoma following BTK inhibitor therapy. The combination remains investigational for this indication, and larger studies are needed to confirm its clinical role.



+91 99030 35498



ishbtmail@gmail.com

Follow |





www.ishbtish.com